Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Trends in immunology

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.it.2008.02.003PMID 18375183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Creating immune privilege: active local suppression that benefits friends, but protects foes

  2008cited by this paper
• The inflammatory response to cell death.

  2008cited by this paper
• Immunological aspects of cancer chemotherapy

  2008cited by this paper
• Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.

  2008cited by this paper
• Tregs and rethinking cancer immunotherapy.

  2007cited by this paper
• Tumors Hamper the Immunogenic Competence of CD4+ T Cell-Directed Dendritic Cell Vaccination1

  2007cited by this paper
• Drug resistance and the solid tumor microenvironment.

  2007cited by this paper
• IFN-γ mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy

  2007cited by this paper
• Taking dendritic cells into medicine

  2007cited by this paper
• AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

  2007cited by this paper
• PD-1 and its ligands in T-cell immunity.

  2007cited by this paper
• Clinical practice. Localized prostate cancer.

  2007cited by this paper
• Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.

  2007cited by this paper
• A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.

  2007cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007cited by this paper
• Prostate cancer immunotherapy

  2007cited by this paper
• Calreticulin exposure dictates the immunogenicity of cancer cell death

  2007cited by this paper
• Tumor escape mechanisms in prostate cancer

  2006cited by this paper
• Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

  2006cited by this paper
• Vascular Targeting: Recent Advances and Therapeutic Perspectives

  2006cited by this paper
• Efficiency of recombinant human TNF in human cancer therapy.

  2006cited by this paper
• Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas

  2006cited by this paper
• Drug penetration in solid tumours

  2006cited by this paper
• Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α

  2006cited by this paper
• Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

  2006cited by this paper
• Apoptotic cell removal in development and tissue homeostasis.

  2006cited by this paper
• Human T cell responses against melanoma.

  2006cited by this paper
• Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.

  2006cited by this paper
• Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice.

  2006cited by this paper
• Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.

  2005cited by this paper
• Management of advanced prostate cancer after first-line chemotherapy.

  2005cited by this paper
• Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

  2005cited by this paper
• Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response

  2005cited by this paper
• Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

  2005cited by this paper
• The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration1

  2005cited by this paper
• Dendritic cells as therapeutic vaccines against cancer

  2005cited by this paper
• Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

  2005cited by this paper
• Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.

  2005cited by this paper
• Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications.

  2005cited by this paper
• Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.

  2005cited by this paper
• Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization

  2005cited by this paper
• Immune surveillance and anti-tumor immune responses: an anatomical perspective.

  2005cited by this paper
• Collagenase Increases the Transcapillary Pressure Gradient and Improves the Uptake and Distribution of Monoclonal Antibodies in Human Osteosarcoma Xenografts

  2004cited by this paper
• Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity.

  2004cited by this paper
• Coupling Tumor Necrosis Factor-α with αV Integrin Ligands Improves Its Antineoplastic Activity

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Tumor Physiology and Drug Resistance

  2004cited by this paper
• Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.

  2004cited by this paper
• Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

  2004cited by this paper
• Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation

  2003cited by this paper
• Combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin against murine and human tumors in vivo

  2003cited by this paper
• Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1

  2003cited by this paper
• Current uses of isolated limb perfusion in the clinic and a model system for new strategies.

  2003cited by this paper
• Immunomodulation in cancer therapeutics.

  2003cited by this paper
• Does the immune system see tumors as foreign or self?

  2003cited by this paper
• Localized prostate cancer

  2003cited by this paper
• Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation.

  2003cited by this paper
• Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.

  2002cited by this paper
• Specialization of tumour vasculature

  2002cited by this paper
• Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells.

  2002cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

  2000cited by this paper
• Apoptosis, cross-presentation, and the fate of the antigen specific immune response

  2000cited by this paper
• TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects

  2000cited by this paper
• Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)

  2000cited by this paper
• Management of advanced prostate cancer.

  2000cited by this paper
• Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma1

  2000cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines.

  1999cited by this paper
• Prostate cancer in a transgenic mouse.

  1995cited by this paper
• Barriers to drug delivery in solid tumors.

  1994cited by this paper
• Severe immunodeficiency in patients treated with fludarabine monophosphate

  1993cited by this paper
• Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.

  1987cited by this paper
• Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity

  1974cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii

  year unknowncited by this paper

• Chimeric antigen receptor–based cell therapy for treating urological tumors

  2025cites this paper
• Targeting endothelial permeability in the EPR effect.

  2023cites this paper
• The blood-prostate barrier: an obstacle to drug delivery into the prostate.

  2023cites this paper
• Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors

  2021cites this paper
• Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotherapy

  2020cites this paper
• Apoptosis Induced by ESC-3 Through Notch Signaling Pathway and Mitochondrial Membrane Potential (ΔΨm) in Liver Cancer

  2019cites this paper
• Cancer Stem Cell Resistance to Targeted Therapy

  2019cites this paper
• Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy

  2019cites this paper
• Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma

  2018cites this paper
• T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.

  2017cites this paper
• Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity

  2017cites this paper
• Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors.

  2017cites this paper
• Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer.

  2017cites this paper
• Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer

  2017cites this paper
• Adoptive transfer of tumor specific T cells from allogeneic donors is feasible, effective and safe alternative to autologous T cell based tumor immunotherapy

  2016cites this paper
• Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotherapy

  2015cites this paper
• Adoptive T‐cell therapy for cancer: The era of engineered T cells

  2015cites this paper
• Targeting the tumor vasculature to enhance T cell activity

  2015cites this paper
• Ways to improve tumor uptake and penetration of drugs into solid tumors

  2014cites this paper
• Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes

  2013cites this paper
• Enhanced siRNA delivery using a combination of an arginine-grafted bioreducible polymer, ultrasound, and microbubbles in cancer cells.

  2013cites this paper
• Won’t you come on in? How to favor lymphocyte infiltration in tumors

  2012cites this paper
• Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy

  2012cites this paper
• Targeted Drug Delivery and Penetration Into Solid Tumors

  2012cites this paper
• Modulators of Arginine Metabolism Do Not Impact on Peripheral T-Cell Tolerance and Disease Progression in a Model of Spontaneous Prostate Cancer

  2011cites this paper
• regression of large tumors across major histocompatibility barriers Adoptive transfer of allogeneic tumor-specific T cells mediates effective

  2011cites this paper
• Pathways of chemotherapy resistance in castration-resistant prostate cancer.

  2011cites this paper
• Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.

  2010cites this paper
• Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF

  2010cites this paper
• Concomitant Tumor and Autoantigen Vaccination Supports Renal Cell Carcinoma Rejection

  2010cites this paper
• A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery.

  2010cites this paper
• Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43).

  2010cites this paper
• Cellular immunotherapy (CI), where have we been and where are we going?

  2009cites this paper
• Inflammation, Aging, and Cancer: Tumoricidal Versus Tumorigenesis of Immunity

  2009cites this paper
• Flagellum-Mediated Biofilm Defense Mechanisms of Pseudomonas aeruginosa against Host-Derived Lactoferrin

  2009influential citation
• Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies

  2009cites this paper
• Non-Redundant Role for IL-12 and IL-27 in Modulating Th2 Polarization of Carcinoembryonic Antigen Specific CD4 T Cells from Pancreatic Cancer Patients

  2009cites this paper
• Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

  2008cites this paper